Model-Based Strategy for 6-Mercaptopurine Treatment in Acute Lymphoblastic Leukemia Maintenance Phase: Prediction of 6-TGN and 6-MMP Concentrations to Optimize Treatment. | Synapse
February 27, 2026
Model-Based Strategy for 6-Mercaptopurine Treatment in Acute Lymphoblastic Leukemia Maintenance Phase: Prediction of 6-TGN and 6-MMP Concentrations to Optimize Treatment.
Key Points
The research aims to optimize 6-mercaptopurine (6-MP) treatment in leukemia by predicting drug concentrations.
Developed a model to predict 6-TGN and 6-MMP concentrations during treatment.
Examined the impact of allopurinol co-treatment on 6-MP dosing.
Conducted evaluations to assess treatment toxicity and efficacy.
Allopurinol co-treatment reduced toxicity associated with 6-MP.
Therapeutic efficacy was maintained at lower 6-MP doses.
The model shows potential for clinical relevance but requires further validation.
Abstract
Allopurinol co-treatment reduces toxicity while maintaining therapeutic efficacy at lower 6-MP doses. The proposed model warrants prospective evaluation for clinical relevance confirmation.